 Connection
Aaron Michels to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Aaron Michels has written about Antibodies, Monoclonal, Humanized.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.428 |
|
|
|
-
Karakus KE, Chesshir L, Walker S, Baschal EE, McDaniel KA, Triolo TM, Steck AK, Frohnert BI, Gottlieb PA, Michels AW, Simmons KM. Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes. Diabetologia. 2026 May; 69(5):1164-1175.
Score: 0.151
-
Michels AW, Gottlieb PA, Nelson B, Dayan C. Autoimmune Type 1 Diabetes in the Era of Disease-Modifying Immune Therapy. Diabetes Metab Res Rev. 2025 10; 41(7):e70091.
Score: 0.148
-
Simmons K, Michels AW. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. Rheum Dis Clin North Am. 2014 Nov; 40(4):797-811.
Score: 0.069
-
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013 Feb; 56(2):391-400.
Score: 0.060
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|